# Adversarial re-verification verdict — malignant_spinal_cord_compression.md

Checked against DeVita, Hellman, Rosenberg's Cancer: Principles & Practice of Oncology, 12th ed.,
Chapter 81 "Spinal Cord Compression" (lines 313142-313900 of devita.txt, full chapter body through
the reference list).

## 1. DOSE LEAK
All numeric tokens present, with verdict on each:
- "72 hours" — clinical timing threshold (matches source's ">72 hours"), not a dose.
- "roughly two months" / "under about three months" — prognostic thresholds in words (match
  source's ">2 months" / "<3 months"), not numeric doses/schedules.
- "grade 2 to 3" (x2) and "grade 0 to 1" (x1) — Bilsky grade numbers (0-3 scale), not doses.
- "radium-223" — isotope name, not a dose.
- "12th ed." — citation edition, not a page number.
- Step 1/2/3/4 section headers — not doses.
No mg, mg/m2, AUC, Gy, or numbered fractionation schedule appears anywhere. Source numbers (10 mg vs
100 mg dexamethasone, 1-3 mm SBRT margin, 4 Gy, 84% vs 57%/OR 6.2/95% CI, >80%/<50% local-control
percentages, threefold retreatment-rate figure) are all correctly converted to qualitative language.
**Verdict: none.**

## 2. UNGROUNDED / MISLABELLED CLAIMS
None found. Every specific claim traces to DeVita Ch.81 (histology-first triage, steroid-before-biopsy
lymphoma pitfall, corticosteroid dosing philosophy, >2-month prognosis gate, MNOP framework and its
ISOC attribution, Table 81.2 radiosensitivity tiers, Patchell-style RCT + Rades matched-pair surgery
findings, surgery risk factors and <3-month cutoff, sSBRT dose/margin rationale, systemic-therapy
indications, radium-223's short alpha path length, grade 2-3 = oncologic emergency with the CSF-
obliteration distinction) or is explicitly labeled "(general oncology standard, not from DeVita's
section on this disease)" (gastroprotection; VTE prophylaxis/log-roll precautions). The grade 0/1
SBRT-eligibility line now reads "grade 0 is the ideal candidate, with select grade 1 cases also
eligible" — matches DeVita's "select cases of grade 1... but the ideal case is grade 0" precisely;
the prior over-generalization is fixed. No claim is mis-attributed to DeVita.
One non-blocking cosmetic note: the second sentence of "Role of systemic therapy" ("Systemic therapy
directed at myeloma, lymphoma, prostate, and breast cancer...") duplicates the (correctly grounded)
first sentence but is tagged as non-DeVita general standard — an inverted/redundant label, not a
fabrication or safety issue, doesn't require another revision cycle.

## 3. CITATION
Present: "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 12th
ed." — name + edition only, no page numbers. Correct format.

## 4. VERDICT: CLEAN (ready for R1 re-review)
Both prior R1 hard-gate issues are resolved:
- Bilsky-grade disclaimer/body contradiction fixed via option (b) — the closing note now says grade
  numbers are retained only where clinically load-bearing (grade 2-3 emergency threshold, grade 0-1
  SBRT-eligibility distinction) and accurately describes what's still deferred (full 0-3 scale, SINS).
- Grade 0/1 SBRT over-generalization softened to match DeVita exactly.
No dose leaks, no ungrounded or DeVita-mis-attributed claims, no dashes found.
